{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:07:33Z","timestamp":1772820453773,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004861","name":"Mackay Memorial Hospital","doi-asserted-by":"publisher","award":["MMH-109-109"],"award-info":[{"award-number":["MMH-109-109"]}],"id":[{"id":"10.13039\/501100004861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["110-2314-B-195-009"],"award-info":[{"award-number":["110-2314-B-195-009"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the frontline treatments in chronic myeloid leukemia (CML). Growing evidence has shown that TKIs also enhance immunity. Since gamma-delta T (\u03b3\u03b4T) cells possess the potent anticancer capability, here we investigated the potential involvement of \u03b3\u03b4T cells in TKI treatments for CML. We characterized \u03b3\u03b4T cells isolated from chronic-phase CML patients before and during TKI treatments. \u03b3\u03b4T expression increased significantly in CML patients who achieved major molecular response (MMR) and deep molecular response (DMR). Their V\u03b42 subset of \u03b3\u03b4T also expanded, and increased expression of activating molecules, namely IFN-\u03b3, perforin, and CD107a, as well as \u03b3\u03b4T cytotoxicity. Mechanistically, TKIs augmented the efflux of isopentenyl pyrophosphate (IPP) from CML cells, which stimulated IFN-\u03b3 production and \u03b3\u03b4T expansion. Notably, the size of the IFN-\u03b3<jats:sup>+<\/jats:sup> na\u00efve \u03b3\u03b4T population in TKI-treated CML patients was strongly correlated with their rates to reach DMR and with the duration on DMR. Statistical analysis suggests that a cutoff of 7.5% IFN-\u03b3<jats:sup>+<\/jats:sup> na\u00efve subpopulation of \u03b3\u03b4T in CML patients could serve as a determinant for MR<jats:sup>4.0<\/jats:sup> sustainability. Our results highlight \u03b3\u03b4T cells as a positive regulator for TKI responses in CML patients.<\/jats:p>","DOI":"10.1038\/s41408-021-00572-7","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T10:02:57Z","timestamp":1637056977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Activated na\u00efve \u03b3\u03b4 T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia"],"prefix":"10.1038","volume":"11","author":[{"given":"Yu-Cheng","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hao","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Kuang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Wei","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Fang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chih","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-Hong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-I","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Ning","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1629-4141","authenticated-orcid":false,"given":"Caleb G.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"572_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-immunol-032713-120216","volume":"32","author":"YH Chien","year":"2014","unstructured":"Chien YH, Meyer C, Bonneville M. gammadelta T cells: first line of defense and beyond. Annu Rev Immunol. 2014;32:121\u201355.","journal-title":"Annu Rev Immunol"},{"key":"572_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.coi.2006.07.002","volume":"18","author":"M Bonneville","year":"2006","unstructured":"Bonneville M, Scotet E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol. 2006;18:539\u201346.","journal-title":"Curr Opin Immunol"},{"key":"572_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.it.2012.01.006","volume":"33","author":"D Hannani","year":"2012","unstructured":"Hannani D, Ma Y, Yamazaki T, Dechanet-Merville J, Kroemer G, Zitvogel L. Harnessing gammadelta T cells in anticancer immunotherapy. Trends Immunol. 2012;33:199\u2013206.","journal-title":"Trends Immunol"},{"key":"572_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nri3904","volume":"15","author":"B Silva-Santos","year":"2015","unstructured":"Silva-Santos B, Serre K, Norell H. gammadelta T cells in cancer. Nat Rev Immunol. 2015;15:683\u201391.","journal-title":"Nat Rev Immunol"},{"key":"572_CR5","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1084\/jem.171.5.1597","volume":"171","author":"CM Parker","year":"1990","unstructured":"Parker CM, Groh V, Band H, Porcelli SA, Morita C, Fabbi M, et al. Evidence for extrathymic changes in the T cell receptor gamma\/delta repertoire. J Exp Med. 1990;171:1597\u2013612.","journal-title":"J Exp Med"},{"key":"572_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/1074-7613(95)90178-7","volume":"3","author":"CT Morita","year":"1995","unstructured":"Morita CT, Beckman EM, Bukowski JF, Tanaka Y, Band H, Bloom BR, et al. Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Immunity. 1995;3:495\u2013507.","journal-title":"Immunity"},{"key":"572_CR7","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","volume":"102","author":"F Dieli","year":"2003","unstructured":"Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood. 2003;102:2310\u20131.","journal-title":"Blood"},{"key":"572_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1084\/jem.20021500","volume":"197","author":"HJ Gober","year":"2003","unstructured":"Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197:163\u20138.","journal-title":"J Exp Med"},{"key":"572_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15663","volume":"8","author":"B Castella","year":"2017","unstructured":"Castella B, Kopecka J, Sciancalepore P, Mandili G, Foglietta M, Mitro N, et al. The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vgamma9Vdelta2 T cell activation by dendritic cells. Nat Commun. 2017;8:15663.","journal-title":"Nat Commun"},{"key":"572_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJM199903043400914","volume":"340","author":"V Kunzmann","year":"1999","unstructured":"Kunzmann V, Bauer E, Wilhelm M. Gamma\/delta T-cell stimulation by pamidronate. N. Engl J Med. 1999;340:737\u20138.","journal-title":"N. Engl J Med"},{"key":"572_CR11","doi-asserted-by":"publisher","first-page":"8118","DOI":"10.4049\/jimmunol.0900101","volume":"182","author":"J Li","year":"2009","unstructured":"Li J, Herold MJ, Kimmel B, Muller I, Rincon-Orozco B, Kunzmann V, et al. Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells. J Immunol. 2009;182:8118\u201324.","journal-title":"J Immunol"},{"key":"572_CR12","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-10-3862","volume":"71","author":"I Benzaid","year":"2011","unstructured":"Benzaid I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkkonen J, et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 2011;71:4562\u201372.","journal-title":"Cancer Res"},{"key":"572_CR13","doi-asserted-by":"publisher","first-page":"8175","DOI":"10.1073\/pnas.91.17.8175","volume":"91","author":"Y Tanaka","year":"1994","unstructured":"Tanaka Y, Sano S, Nieves E, De Libero G, Rosa D, Modlin RL, et al. Nonpeptide ligands for human gamma delta T cells. Proc Natl Acad Sci USA. 1994;91:8175\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"572_CR14","doi-asserted-by":"publisher","first-page":"998","DOI":"10.4049\/jimmunol.154.3.998","volume":"154","author":"JF Bukowski","year":"1995","unstructured":"Bukowski JF, Morita CT, Tanaka Y, Bloom BR, Brenner MB, Band H. V gamma 2V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. J Immunol. 1995;154:998\u20131006.","journal-title":"J Immunol"},{"key":"572_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/375155a0","volume":"375","author":"Y Tanaka","year":"1995","unstructured":"Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature. 1995;375:155\u20138.","journal-title":"Nature"},{"key":"572_CR16","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/sj.bmt.1703043","volume":"27","author":"H Dolstra","year":"2001","unstructured":"Dolstra H, Fredrix H, van der Meer A, de Witte T, Figdor C, van de Wiel-van Kemenade E. TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transpl. 2001;27:1087\u201393.","journal-title":"Bone Marrow Transpl"},{"key":"572_CR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/sj.bmt.1702830","volume":"27","author":"LS Lamb Jr.","year":"2001","unstructured":"Lamb LS Jr., Musk P, Ye Z, van Rhee F, Geier SS, Tong JJ, et al. Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transpl. 2001;27:601\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"572_CR18","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938\u201345.","journal-title":"Nat Med"},{"key":"572_CR19","doi-asserted-by":"publisher","first-page":"e1284723","DOI":"10.1080\/2162402X.2017.1284723","volume":"6","author":"M Tosolini","year":"2017","unstructured":"Tosolini M, Pont F, Poupot M, Vergez F, Nicolau-Travers ML, Vermijlen D, et al. Assessment of tumor-infiltrating TCRVgamma9Vdelta2 gammadelta lymphocyte abundance by deconvolution of human cancers microarrays. Oncoimmunology. 2017;6:e1284723.","journal-title":"Oncoimmunology"},{"key":"572_CR20","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.4049\/jimmunol.0903454","volume":"184","author":"M D\u2019Asaro","year":"2010","unstructured":"D\u2019Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, et al. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol. 2010;184:3260\u20138.","journal-title":"J Immunol"},{"key":"572_CR21","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl J Med. 2010;362:2260\u201370.","journal-title":"N. Engl J Med"},{"key":"572_CR22","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl J Med. 2010;362:2251\u20139.","journal-title":"N. Engl J Med"},{"key":"572_CR23","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N. Engl J Med. 2017;376:917\u201327.","journal-title":"N. Engl J Med"},{"key":"572_CR24","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747\u201357.","journal-title":"Lancet Oncol"},{"key":"572_CR25","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6:e375\u2013e83.","journal-title":"Lancet Haematol"},{"key":"572_CR26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","volume":"35","author":"JP Radich","year":"2021","unstructured":"Radich JP, Hochhaus A, Masszi T, Hellmann A, Stentoft J, Casares MTG, et al. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 2021;35:1344\u201355.","journal-title":"Leukemia"},{"key":"572_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11899-013-0190-1","volume":"9","author":"M Ilander","year":"2014","unstructured":"Ilander M, Hekim C, Mustjoki S. Immunology and immunotherapy of chronic myeloid leukemia. Curr Hematol Malig Rep. 2014;9:17\u201323.","journal-title":"Curr Hematol Malig Rep"},{"key":"572_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","volume":"8","author":"A Hughes","year":"2017","unstructured":"Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017;8:469.","journal-title":"Front Immunol"},{"key":"572_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","volume":"21","author":"B Zhang","year":"2012","unstructured":"Zhang B, Ho YW, Huang Q, Maeda T, Lin A, Lee SU, et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012;21:577\u201392.","journal-title":"Cancer Cell"},{"key":"572_CR30","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3390\/ijms18081824","volume":"18","author":"N Mukaida","year":"2017","unstructured":"Mukaida N, Tanabe Y, Baba T. Chemokines as a conductor of bone marrow microenvironment in chronic myeloid leukemia. Int J Mol Sci. 2017;18:1824.","journal-title":"Int J Mol Sci"},{"key":"572_CR31","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26:2172\u20135.","journal-title":"Leukemia"},{"key":"572_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0022-1759(01)00359-3","volume":"253","author":"H Lecoeur","year":"2001","unstructured":"Lecoeur H, Fevrier M, Garcia S, Riviere Y, Gougeon ML. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods. 2001;253:177\u201387.","journal-title":"J Immunol Methods"},{"key":"572_CR33","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1084\/jem.20030235","volume":"198","author":"F Dieli","year":"2003","unstructured":"Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C, et al. Differentiation of effector\/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med. 2003;198:391\u20137.","journal-title":"J Exp Med"},{"key":"572_CR34","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.it.2016.07.006","volume":"37","author":"SJ Lalor","year":"2016","unstructured":"Lalor SJ, McLoughlin RM. Memory gammadelta T cells-newly appreciated protagonists in infection and immunity. Trends Immunol. 2016;37:690\u2013702.","journal-title":"Trends Immunol"},{"key":"572_CR35","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.3389\/fimmu.2018.02636","volume":"9","author":"C Khairallah","year":"2018","unstructured":"Khairallah C, Chu TH, Sheridan BS. Tissue adaptations of memory and tissue-resident gamma delta T cells. Front Immunol. 2018;9:2636.","journal-title":"Front Immunol"},{"key":"572_CR36","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"572_CR37","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/sj.leu.2404139","volume":"20","author":"DM Ross","year":"2006","unstructured":"Ross DM, Branford S, Moore S, Hughes TP. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia. 2006;20:664\u201370.","journal-title":"Leukemia"},{"key":"572_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ejh.12969","volume":"100","author":"K Murai","year":"2018","unstructured":"Murai K, Yamaguchi K, Ito S, Miyagishima T, Shindo M, Wakasa K, et al. Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients. Eur J Haematol. 2018;100:27\u201335.","journal-title":"Eur J Haematol"},{"key":"572_CR39","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.3390\/cancers12092521","volume":"12","author":"G Etienne","year":"2020","unstructured":"Etienne G, Dulucq S, Bauduer F, Adiko D, Lifermann F, Dagada C, et al. Incidences of deep molecular responses and treatment-free remission in de Novo CP-CML patients. Cancers (Basel). 2020;12:2521","journal-title":"Cancers (Basel)"},{"key":"572_CR40","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","volume":"85","author":"P Rohon","year":"2010","unstructured":"Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol. 2010;85:387\u201398.","journal-title":"Eur J Haematol"},{"key":"572_CR41","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/eji.200525983","volume":"35","author":"N Caccamo","year":"2005","unstructured":"Caccamo N, Meraviglia S, Ferlazzo V, Angelini D, Borsellino G, Poccia F, et al. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets. Eur J Immunol. 2005;35:1764\u201372.","journal-title":"Eur J Immunol"},{"key":"572_CR42","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","volume":"129","author":"A Hughes","year":"2017","unstructured":"Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood. 2017;129:1166\u201376.","journal-title":"Blood"},{"key":"572_CR43","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.4049\/jimmunol.181.10.6955","volume":"181","author":"N Larmonier","year":"2008","unstructured":"Larmonier N, Janikashvili N, LaCasse CJ, Larmonier CB, Cantrell J, Situ E, et al. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol. 2008;181:6955\u201363.","journal-title":"J Immunol"},{"key":"572_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-22","volume":"9","author":"F Fei","year":"2010","unstructured":"Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, et al. Effects of nilotinib on regulatory T cells: the dose matters. Mol Cancer. 2010;9:22.","journal-title":"Mol Cancer"},{"key":"572_CR45","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1158\/1535-7163.MCT-14-0849","volume":"14","author":"L Christiansson","year":"2015","unstructured":"Christiansson L, Soderlund S, Mangsbo S, Hjorth-Hansen H, Hoglund M, Markevarn B, et al. The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses. Mol Cancer Ther. 2015;14:1181\u201391.","journal-title":"Mol Cancer Ther"},{"key":"572_CR46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.leukres.2018.01.010","volume":"66","author":"Y Najima","year":"2018","unstructured":"Najima Y, Yoshida C, Iriyama N, Fujisawa S, Wakita H, Chiba S, et al. Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study. Leuk Res. 2018;66:66\u201372.","journal-title":"Leuk Res"},{"key":"572_CR47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13684730210002319","volume":"7","author":"JM Aswald","year":"2002","unstructured":"Aswald JM, Lipton JH, Aswald S, Messner HA. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. Cytokines Cell Mol Ther. 2002;7:143\u20139.","journal-title":"Cytokines Cell Mol Ther"},{"key":"572_CR48","doi-asserted-by":"publisher","first-page":"e1638210","DOI":"10.1080\/2162402X.2019.1638210","volume":"8","author":"A Kreutzman","year":"2019","unstructured":"Kreutzman A, Yadav B, Brummendorf TH, Gjertsen BT, Hee Lee M, Janssen J, et al. Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. Oncoimmunology. 2019;8:e1638210.","journal-title":"Oncoimmunology"},{"key":"572_CR49","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110:4055\u201363.","journal-title":"Blood"},{"key":"572_CR50","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/leu.2010.11","volume":"24","author":"KC Lee","year":"2010","unstructured":"Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers MJ. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia 2010;24:896\u2013900.","journal-title":"Leukemia"},{"key":"572_CR51","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3324\/haematol.13151","volume":"94","author":"DH Kim","year":"2009","unstructured":"Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, et al. Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 2009;94:135\u20139.","journal-title":"Haematologica"},{"key":"572_CR52","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","volume":"116","author":"A Kreutzman","year":"2010","unstructured":"Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, et al. Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116:772\u201382.","journal-title":"Blood"},{"key":"572_CR53","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s12185-010-0565-1","volume":"91","author":"Y Nagata","year":"2010","unstructured":"Nagata Y, Ohashi K, Fukuda S, Kamata N, Akiyama H, Sakamaki H. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol. 2010;91:799\u2013807.","journal-title":"Int J Hematol"},{"key":"572_CR54","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.2174\/092986711798184271","volume":"18","author":"M Krusch","year":"2011","unstructured":"Krusch M, Salih HR. Effects of BCR-ABL inhibitors on anti-tumor immunity. Curr Med Chem. 2011;18:5174\u201384.","journal-title":"Curr Med Chem"},{"key":"572_CR55","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1582-4934.2009.00500_1.x","volume":"13","author":"SJ Blake","year":"2009","unstructured":"Blake SJ, Lyons AB, Hughes TP. Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro. J Cell Mol Med. 2009;13:599\u2013601.","journal-title":"J Cell Mol Med"},{"key":"572_CR56","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1126\/science.1110267","volume":"309","author":"M Brandes","year":"2005","unstructured":"Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science. 2005;309:264\u20138.","journal-title":"Science"},{"key":"572_CR57","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/eji.201141870","volume":"42","author":"F Pont","year":"2012","unstructured":"Pont F, Familiades J, Dejean S, Fruchon S, Cendron D, Poupot M, et al. The gene expression profile of phosphoantigen-specific human gammadelta T lymphocytes is a blend of alphabeta T-cell and NK-cell signatures. Eur J Immunol. 2012;42:228\u201340.","journal-title":"Eur J Immunol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00572-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T23:05:33Z","timestamp":1675897533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00572-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":57,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["572"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00572-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]},"assertion":[{"value":"25 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}